Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7SUmY{Oi53IN88US=> M2nvPVEuPCCm MVLEUXNQ MoPL[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> MVeyOVQ6ODN6Mx?=
H1703 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;icVIvPSEQvF2= NVfC[2s2OS12IHS= Mnr2SG1UVw>? NWfmSmJ6\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? NXfrbJlNOjV2OUCzPFM>
HUVECs MoXYR5l1d3SxeHnjbZR6KEG|c3H5 NVnQWnR{OTByIH7N NU\xO2o3OjRiaB?= NEDLZ2RifHSnboXheIV{KHSqZTDhZpJw\2G2aY\lJIVn\mWldIOgc4Yh[2GueXPvd4lvKG:wIG\STU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NUjtOo9vOjV2NUCxPFY>
APRE-19 MYnBdI9xfG:|aYOgRZN{[Xl? MX61JO69VQ>? NUD5Umo4OjRiaB?= Mn\BZYJwdGm|aHXzJGZNYi2vZXTpZZRm\CCycn:td5Vzfmm4YXyvZY51cS2jcH;weI9{cXNiYXP0bZZqfHl? NXPIbHhUOjV|Mkm2NVc>
MDA-MB-231 M{LEbGFxd3C2b4Ppd{BCe3OjeR?= M4CyR|HDqM7:TdMg MVm0PEBp M{flbWROW09? NWnhbHZo\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKHS{ZXH0[YQhf2m2aDCyOUDPxE1ib3[gSlEhd3JiRkKgxsA> MXSyOVMxODl|Mh?=
MCF7 NHLZ[|JHfW6ldHnvckBCe3OjeR?= NFv1c|EyODBibl2= M4XsWlI1KGh? MmDI[YxqdWmwYYTld{BGOi2rbnT1Z4VlKEGURT3MeYMh[WO2aY\peJk> MXmyOVE4OjV3Nx?=
HT-29  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXDToIyNjYEoNM1US=> NEDQfVY6PiCq NXTkXnVT\GWlcnXhd4V{KGOnbHyg[5Jwf3SqIIfobYNpKGOjbjDi[UBqdmirYnn0[YQh[nliS2nORS=> NG\5eXMzPTBzMkGyNy=>
MO59K  NY\4cmVQS3m2b4TvfIlkcXS7IFHzd4F6 NYjvbHZUPcLizszN MnvJO{Bl M1;Xd2ROW09? MoTF[Y5p[W6lZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw MWmyOFk2OzV4MR?=
MO59J MXzDfZRwfG:6aXPpeJkhSXO|YYm= MoPWOeKh|ryP NFnnemw4KGR? NVvIcoRsTE2VTx?= NXv2WlZG\W6qYX7j[ZMhfGinIHP5eI91d3irY3n0fUBw\iCndH;wc5Nq\GVib4KgZ4l{eGyjdHnu MWiyOFk2OzV4MR?=
MO59K  Ml;FRZBweHSxc3nzJGF{e2G7 NYO3R5NLOTBizszN NGfFc4ozPCCq MX7EUXNQ NUPrbXFtcW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw M2TsVVI1QTV|NU[x
MO59J NIjqOG9CeG:ydH;zbZMhSXO|YYm= M{HZWVExKM7:TR?= NXThPIZIOjRiaB?= M3fyfWROW09? NWDENpV3cW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw NHzhW4QzPDl3M{W2NS=>
HepG2 M3P2OWZ2dmO2aX;uJGF{e2G7 MY[xNFAhdk1? NE[2S4sxNjViaB?= MUXEUXNQ NGnEeVdjdG:la4OgUWEucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v NELOc4szPDh4M{O1NC=>
A549  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13HTFMhyrWPwrC= M37HUVIhcA>? NXm4dJhme3WycILld5NmeyCyZX3leJJmgGWmLXnu[JVk\WRiQXv0JIFv\CCJU1uz{tIh[WO2aY\heIlwdixiUz3wbIF{\SCjcoLld5QtKGOnbHygZZBweHSxc3nzJIFv\CClYYPwZZNmNTNiYXP0bZZifGmxbh?= NH3nTlQzPDh2N{i2Ny=>
A549  NU\tPVJITnWwY4Tpc44hSXO|YYm= MmjnNVDDqM7:bdMg NV7WT|lXOTZiaB?= M4DGNGROW09? Mkn0cY9lfWyjdHXzJJRp\SCLQW[gdoVxdGmlYYTpc44h[W6mIHPheZNmeyC{ZYTlcpRqd25ib3[gUnAhcW5idHjlJI52[2yndYOu NYDmXHBPOjR6MEKxNVE>
SK-N-LO NXzRRmVmTnWwY4Tpc44hSXO|YYm= MVOxNFAhdk1? MmXzNE42KGh? NHLOPXJl\WO{ZXHz[ZMhfGinIIP0bY12dGGwdDDl[oZm[3S|IH;mJI1wenCqaX7lJI9vKEGtdDDwbI9{eGixconsZZRqd25? M4m0ZVI1PjV2NkC2
HL-60 M3HSXGZ2dmO2aX;uJGF{e2G7 NEG4ZmwxNjIEoN88US=> MoX6O|IhcA>? Mnn2Zoxw[2u|IHThd4F1cW6rYj3pcoR2[2WmIHPlcIwh\GmoZnXy[Y51cWG2aX;u NY\RN|FoOjR4MEeyO|M>
HepG2  NXHPTphHTnWwY4Tpc44hSXO|YYm= MUOyNFAhdk1? NWHYdVlpOC53IHi= NY[ze3Nt[XS2ZX71ZZRmeyCIb4jPJJBpd3OyaH;yfYxifGmxbh?= MWWyOFU{PTF7Mh?=
H520 NHL1WHJHfW6ldHnvckBCe3OjeR?= MXixNOKh|ryP M1PT[|EhcA>? MYfEUXNQ Mn\1[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz NW\qeolFOjR2NEe5N|U>
H1975 MV\GeY5kfGmxbjDBd5NigQ>? MVWxNOKh|ryP M3fVRlEhcA>? MXHEUXNQ NX31NFNn\GWlcnXhd4V{KGOnbHz1cIFzKHCqb4PwbI8uSUuWIIDyc5RmcW5ibHX2[Yx{ M3j4TVI1PDR5OUO1
MG-63 MVHBdI9xfG:|aYOgRZN{[Xl? NVTyVGxyOTBiwsXN M{nrNVEzKGh? NVTMb3A3\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? NYTMVHRqOjR|NUizNFE>
5637 NVzNUJZxSXCxcITvd4l{KEG|c3H5 M{Wzb|ExyqEQvF2= MY[0NEBucW5? NEm4fFFz\X[ncoPld{BxOjGZQV[xJIV5eHKnc4Ppc44tKEOGSzDlfJBz\XO|aX;uMEBidmRiY3XscEBqdmirYnn0bY9vKGmwZIXj[YQh[nliZoXjc4ll[W5? Mn7INlQ{OzN6Nki=
HEK-293 M3noTGZ2dmO2aX;uJGF{e2G7 NVL4O|lHOTVybl2= MofsNVYhcA>? M2OyS2ROW09? NVXmRlV{\GWlcnXhd4V{KEOUVDDhZ5Rqfmm2eR?= NGnBRoUzPDN{NEO2Oi=>
SW480  NVrDT3c4TnWwY4Tpc44hSXO|YYm= NVP5O4JGOTVybl2= M3\xfVIxKGh? M4DWcGROW09? MXry[YR2[2W|IHPlcIx2dGG{IHHjZ5VufWyjdHnvckBw\iEQsj3jZZRmdmmw M{\OO|I1OzJ2M{[2
HepG2 NHeySmdHfW6ldHnvckBCe3OjeR?= MXqxNFAhdk1? M4\KfFI1KGh? MWjheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? NIi3[nEzPDJ7N{WxNC=>
HCT 116  M165W2Z2dmO2aX;uJGF{e2G7 NXPOd5JNOTByIH7N M1:0VFI1KGh? MnrGZZR1\W63YYTld{B1cGViY3;sc45q\XNib3[geIhmKHS3bX;yJINmdGy|IIfpeIghfXC{ZXf1cIF1cW:wIH;mJGFsfDF? Mn\DNlQzQTd3MUC=
BEL/FU NGGyUotHfW6ldHnvckBCe3OjeR?= MlzYNUBuVQ>? NF30UGQzPCCq M{PqN4Rm[3KnYYPld{Bxem:2ZXnuJIxmfmWuczDv[kB1cGViUFmzT{9Cc3RicHH0bJdigQ>? MlfuNlQzOzJyOUm=
Huh7  NF\4XJlHfW6ldHnvckBCe3OjeR?= MnftN:Kh|ryP NXvCZVdqOSCq NXmwR5ptemWmdXPld{B1cGVidnnyeZMh\W62comgbY51dyC2aHWgZ4VtdHN? NWXhfXpWOjRzOESxPVY>
A-375 M3LFZ2Fxd3C2b4Ppd{BCe3OjeR?= M3vkTFQwQCEQvF2= M3jMRlI1KGh? NYLSTXpz\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NVXae5ZOOjRzMUOxO|M>
A-375-TS  MWrBdI9xfG:|aYOgRZN{[Xl? M2LtZ|QwQCEQvF2= M3;De|I1KGh? MUDlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MUeyOFEyOzF5Mx?=
Mel-HO MXXBdI9xfG:|aYOgRZN{[Xl? MYq0M|gh|ryP NEHrO3ozPCCq NXnneYdQ\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MXyyOFEyOzF5Mx?=
Mel-HO-TS M1[0PGFxd3C2b4Ppd{BCe3OjeR?= MYG0M|gh|ryP NHLVTZczPCCq M2HWU4VvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NID3WmwzPDFzM{G3Ny=>
MeWo M3qwOWFxd3C2b4Ppd{BCe3OjeR?= MXe0M|gh|ryP MkjuNlQhcA>? M3LWfIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MWiyOFEyOzF5Mx?=
Mel-2a Mlz6RZBweHSxc3nzJGF{e2G7 MXy0M|gh|ryP MUOyOEBp M2LHNIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MXKyOFEyOzF5Mx?=
MDA-MB-231 M3HTdmZ2dmO2aX;uJGF{e2G7 M4PZT|DjiJN2MECgcm0> MUO0JIg> MVjzeZBxemW|c3XzJGFsfCCyaH;zdIhwenmuYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYLpfZNTOjJ7ME[yOVk>
MDA-MB-231 NETBTIdHfW6ldHnvckBCe3OjeR?= MWi0NFAhdk1? MUe0JIg> NGLuelVl\WO{ZXHz[ZMhVU2SLUmgZY5lKEmOLUigdJJwfGWrbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFPyOmYzOjlyNkK1PS=>
Jurkat NFHVSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfpcZoxNjJ3LUGuNlUh|ryP NHzETYQzPC92ODDo MlvxSG1UVw>? MUHpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? MUGxPVc2PzF6NR?=
Namalwa NWfo[25yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PCXFAvOjVvMT6yOUDPxE1? NFzDOmkzPC92ODDo NV\oRnlbTE2VTx?= NHjzclRqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MYSxPVc2PzF6NR?=
Jurkat MXXBdI9xfG:|aYOgRZN{[Xl? NHrNZWsxNjJ3LUGuNlUh|ryP NWXGNFF2OjRxNEigbC=> NFPZOYJFVVOR M3n2e4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NW\RZ3BTOTl5NUexPFU>
Namalwa MnvaRZBweHSxc3nzJGF{e2G7 NHPHToMxNjJ3LUGuNlUh|ryP NXrWNYtKOjRxNEigbC=> MnPSSG1UVw>? MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= M371e|E6PzV5MUi1
K562 MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXG[2VFOjRiaB?= M4TQZmlEPTB;MkZCtVAvOTRibl2= MUexPVY3OjN4MR?=
SW1990 MV7GeY5kfGmxbjDBd5NigQ>? MnrMNE4xOS1zIN88US=> MWixJIg> MmP0bY5pcWKrdIOgTGEucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v M2PXZVE6PDZ7MEKw
RT112  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\ONVDDqM7:TR?= MWKyOEBp MWXEUXNQ NISwSHZl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? MlvCNVg4QDd6M{K=
MHG-U1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3BXHBEOTEEoN88US=> Mle5NlQhcA>? NHXpOJZFVVOR NFPVVlFl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? MlLpNVg4QDd6M{K=
SMMC-7721 MnLaRZBweHSxc3nzJGF{e2G7 NIC5UnAzODEEoH7N Mn3QNlQhcA>? NGe3bo5qdmO{ZXHz[ZMhS0i[LXnu[JVk\WRiYYDvdJRwe2m| M2XDRlE4PTV5MUmx
SMMC-7721 M4XuOWZ2dmO2aX;uJGF{e2G7 M3jFR|IxOMLibl2= MYqyOEBp Mnf6eZAuemWpdXzheIV{KM7{MTy0S3QyKGW6cILld5Nqd25? Mnv1NVc2PTdzOUG=
HeLa MXfGeY5kfGmxbjDBd5NigQ>? NHrocWIyODEEoH7NxsA> MmO0NUBp NWPENGdW[Wy2ZYLzJJRp\SCvb4LwbI9td2e7IH;mJJRp\SC2cnHud4ZmenKrbjDy[YN6[2yrbnegZ49ueGG{dH3lcpQ> M{XYW|E3QDlyOUG1
MRC5VI MXHGeY5kfGmxbjDBd5NigQ>? M1vhVlEzNjVibV2= NV;KVm5[OC53IHi= NIf1XI5FVVOR MUPhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> M3TR[FE3OjJ5M{m0
AT5BIVA MYPGeY5kfGmxbjDBd5NigQ>? NGTYWlMyOi53IH3N MWGwMlUhcA>? NYn6TXQxTE2VTx?= MWfhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> M3H5T|E3OjJ5M{m0
M059J MkjqSpVv[3Srb36gRZN{[Xl? M2G5dlEzNjVibV2= NFi5RVUxNjViaB?= NWnmdZdUTE2VTx?= MUXhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> NWLRW|dpOTZ{MkezPVQ>
HeLa NYj1[4RwTnWwY4Tpc44hSXO|YYm= M4e5NVEzNjVibV2= MorMNE42KGh? MlzWSG1UVw>? NF3kTJRi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? NX70Xnc2OTZ{MkezPVQ>
N2a NULFT|dJSXCxcITvd4l{KEG|c3H5 MVSwMlEuOTBizszN MkPqNkBp NGn5U4dqdmS3Y3XzJIRm[3KnYYPl[EBk\WyuII\pZYJqdGm2eTDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= NVjSbZpXOTV6NEK3Olc>
Jurkat  MoTtT4lv[XOnIFHzd4F6 NIfiT4lKSzVyIH;mJFI1KG6P MV[xOVY3PDVzOR?=

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID